leadf
logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics - Silence Therapeutics to Participate in Conferences

RNS Number : 5527T
Silence Therapeutics PLC
21 July 2020
 

Silence Therapeutics to Participate in US Virtual Investor Conferences in August

 

21 July 2020

 

LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that Company management will be participating in three virtual conferences, details of which can be found below:

 

William Blair Biotech Focus Conference

 

 

 

Date:

 

Thursday, August 6, 2020

Time:

 

2:00 pm EDT (19:00 BST)

Panel:

 

30 Years of RNA-Targeted Therapies - Where Are We Now

 

BTIG Virtual Biotechnology Conference

 

 

 

Date:

 

Monday, August 10, 2020

Time:

 

9:30 am EDT (14:30 BST)

Webcast link:

 

Silence Therapeutics fireside chat

 

Canaccord 40th Annual Growth Conference

 

 

 

Date:

 

Thursday, August 13, 2020

Time:

 

11:30 am EDT (16:30 BST)

Webcast link:

 

Silence Therapeutics presentation

 

Live webcasts of the BTIG Virtual Biotechnology Conference and the Canaccord Growth Conference can be accessed via the Investors section of the Company's website at www.silence-therapeutics.com. An archived replay of the webcasts will be available for 60 days on the Company's website after the conference.

 

 

 

 

For more information, please contact:

 

Silence Therapeutics plc

Iain Ross, Executive Chairman

Rob Quinn, Chief Financial Officer

 

 

Tel:  +44 (0)20 3457 6900

Investec (Nominated Adviser and Broker)

Daniel Adams/Gary Clarence

 

Tel:  +44 (0) 20 7597 5970

European IR

Consilium Strategic Communications

Mary-Jane Elliott/Chris Welsh/Angela Gray

[email protected]

 

Tel: +44 (0) 20 3709 5700

U.S. IR

Westwicke

Peter Vozzo

[email protected]

 Tel: +1 (443) 213-0505

 

 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCRMMBTMTJTTFM

Quick facts: Silence Therapeutics PLC

Price: 435

Market: AIM
Market Cap: £360.29 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: FTSE 100 retreats as UK employment tumbles

Headlines from the Proactive UK newsroom. The FTSE100 was on the back foot as the new job numbers highlighted how business is suffering due to the pandemic. The blue chip-index shed 60 to 6,232. People on UK payrolls fell by 649,000 between March and June, according to the government....

on 16/7/20